Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 11/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.68 |
| ▸ | SLC2A1 | P11166 | 6/20 | 0.45 |
| ▸ | SLC2A3 | P11169 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18792356 | 0.88 | ROCK2 (0.66) | ROCK2ROCK1SLC2A1SLC2A3CYP1A2 | |
| SCHEMBL17038106 | 0.81 | ROCK2 (1.00) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL23380752 | 0.73 | ROCK2 (0.66) | ROCK2ROCK1SMN1; SMN2KMT2A | |
| SCHEMBL24968782 | 0.71 | KMT2A (0.43) | ROCK2ROCK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL24968709 | 0.71 | KMT2A (0.45) | ROCK2ROCK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL18792334 | 0.71 | ROCK2 (0.71) | ROCK2ROCK1SLC2A1SLC2A3 | |
| SCHEMBL19592078 | 0.70 | ROCK2 (0.66) | ROCK2ROCK1 | |
| SCHEMBL17038100 | 0.69 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL17177130 | 0.69 | ROCK2 (0.62) | ROCK2ROCK1SLC2A1SLC2A3CYP1A2 | |
| SCHEMBL20030093 | 0.69 | ROCK1 (0.64) | ROCK2ROCK1SLC2A1SLC2A3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885SLC2A1 3869/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885SLC2A1 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.